================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF
THE SECURITIES EXCHANGE ACT OF 1934
ENCYSIVE PHARMACEUTICALS INC.
(Name of Subject Company (Issuer))
EXPLORER ACQUISITION CORP.
A WHOLLY-OWNED SUBSIDIARY OF
PFIZER INC.
(Names of Filing Person identifying status as offeror, issuer or other person)
COMMON STOCK, $.005 PAR VALUE PER SHARE
(Title of Class of Securities)
29256X107
(CUSIP Number of Class of Securities)
-------------------
MARGARET M. FORAN, ESQ.
PFIZER INC.
235 EAST 42ND STREET
NEW YORK, NEW YORK, 10017
(212) 573-2323
(Name, address, and telephone numbers of person
authorized to receive notices and
communications on behalf of filing
persons)
COPIES TO:
RAYMOND O. GIETZ
WEIL, GOTSHAL & MANGES LLP
767 FIFTH AVENUE
NEW YORK, NEW YORK, 10153
TELEPHONE: (212) 310-8000
-------------------
--------------------------------------------------------------------------------
CALCULATION OF FILING FEE
--------------------------------------------------------------------------------
Transaction Valuation* Amount of Filing Fee*
--------------------------------------------------------------------------------
Not Applicable* Not Applicable*
--------------------------------------------------------------------------------
* A filing fee is not required in connection with this filing as it relates
solely to preliminary communications made before the commencement of a
tender offer.
|_| Check the box if any part of the fee is offset as provided by Rule
0-11(a)(2) and identify the filing with which the offsetting fee was
previously paid. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
Amount Previously Paid: Not applicable
Form or Registration No.: Not applicable
Filing Party: Not applicable
Date Filed: Not applicable
[X] Check the box if the filing relates solely to preliminary communications
made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the
statement relates:
[X] third-party tender offer subject to Rule 14d-1.
[_] issuer tender offer subject to Rule 13e-4.
[_] going-private transaction subject to Rule 13e-3.
[_] amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing fee is a final amendment reporting the
results of the tender offer: [_]
================================================================================
EXHIBIT INDEX
Exhibit No. Description
99.1 Joint Press Release issued by Pfizer Inc. and Encysive
Pharmaceuticals Inc. dated February 20, 2008.
2